App Logo
DEEN
Get Started
CGHA

B2B SaaS Provider · vs · B2B SaaS Provider · Private Equity, VC & Investor

CGI vs Harris

Structured technology and market comparison · 2026

Direct Feature Comparison

CGI · vs · Harris
Market Cluster / Sector
CGIB2B SaaS Provider
HarrisB2B SaaS Provider · Private Equity, VC & Investor
Platform Focus
CGI

Enterprise consulting and vertical software provider for regulated industries.

Harris

Vertical-market software operator and acquirer for regulated industries.

Company Size
CGI>5,000 employees
Harris>5,000 employees
Headquarters
CGICanada
HarrisCanada
Year Founded
CGI1976
Harris1976
Dossier & Alternatives

Analyze all overlapping signals and tech stacks for CGI and Harris

Compare mutual enterprise clients, monetization models, live market signals, and partner networks directly in the interactive Knowledge Graph.

Compare in PlatformInstant access · 1-click via Google/LinkedIn

Comparison Analysis

What is the main difference between CGI and Harris?

When comparing CGI and Harris, both platforms operate within the B2B SaaS Provider ecosystem. CGI is positioned as Enterprise consulting and vertical software provider for regulated industries, whereas Harris focuses on Vertical-market software operator and acquirer for regulated industries. Decision-makers evaluate both solutions when orchestrating their commercial monetization and technology stack.

What are the top alternatives to CGI and Harris?

When evaluating CGI and Harris, enterprise buyers also consider other platforms in B2B SaaS Provider. You can discover the full competitive landscape and evaluate other alternatives by viewing their respective footprint profiles on Polaris7.

How do the corporate scale, structure, and headquarters of CGI and Harris compare?

CGI is headquartered in Canada (founded in 1976) with >5,000 employees. Harris is based in Canada (founded in 1976) with >5,000 employees. Complete ownership, subsidiary trees, and corporate affiliations are documented across Polaris7.

Market Signals

Recent Market Signals & Activity: CGI vs Harris

Documented market movements, strategic partnerships, product releases, and regulatory developments mapped across Polaris7.

CG

CGI

Recent Signals

  • ·SEC APIfinancials

    8-K Financial Filing Analysis for CGI (2026-11-03)

    On November 3, 2026, Corcept Therapeutics Incorporated furnished a Form 8-K under Items 2.02 and 7.01 announcing the release of its financial results for the third quarter ended September 30, 2026, along with a corporate update. The detailed financial statements and operational metrics were provided via an accompanying press release attached as Exhibit 99.1. The filing fulfills regulatory disclosure requirements under Regulation FD without formal incorporation into Securities Act registration statements.

    • Corcept Therapeutics furnished its Q3 2026 financial results for the period ended September 30, 2026, via an 8-K press release notice on November 3, 2026.
    • The disclosure was furnished pursuant to Item 2.02 (Results of Operations and Financial Condition) and Item 7.01 (Regulation FD Disclosure), with Exhibit 99.1 containing the full press release.
    • The filing was formally signed and authorized by Chief Financial Officer Atabak Mokari on November 3, 2026.
  • ·SEC APIfinancials

    10-Q Financial Filing Analysis for CGI (2026-11-03)

    Corcept Therapeutics reported significant financial growth for Q3 2026, driven by expanding commercial execution across its endocrinology franchise and the initial launch ramp of Lifyorli (relacorilant). Net product revenue rose 64.0% year-over-year to $340.5M, supported by $249.1M in hypercortisolism product sales and a $91.4M contribution from Lifyorli following its April 2026 U.S. launch. Operating income surged tenfold to $114.7M from $10.2M in Q3 2025, benefiting from gross margin expansion (cost of sales at just 1.4% of revenue) and disciplined operating expenditure leverage. Net income reached $126.8M, bolstered by a $6.5M net income tax benefit. Corcept maintains a robust balance sheet with $662.3M in cash and marketable securities and no long-term debt, positioning the company securely as it awaits the PDUFA target review date of December 17, 2026, for relacorilant in hypercortisolism.

    • Q3 2026 net product revenue grew 64.0% year-over-year to $340.47M, with newly approved oncology drug Lifyorli contributing $91.41M and hypercortisolism products generating $249.07M.
    • Operating income for the quarter reached $114.72M compared to $10.22M in Q3 2025, while diluted earnings per common share expanded to $1.01 compared to $0.16.
    • The resubmitted New Drug Application (NDA) for relacorilant in endogenous hypercortisolism has an assigned PDUFA target action date of December 17, 2026.
  • ·CGI

    CGI named a Leader in the 2026 IDC MarketScape vendor assessment of worldwide trade finance systems

    CGI has been named a Leader in the 2026 IDC MarketScape vendor assessment of worldwide trade finance systems, a significant industry recognition for the company's trade finance technology leadership.

View all signals for CGI →
HA

Harris

Recent Signals

No recent market signals documented for Harris in the current tracking window.

View all signals for Harris →

Compare their exact ecosystem overlaps.

Explore all deep relationships in Polaris7. Discover exactly which mutual clients, integrated technologies, and overlapping partners CGI and Harris share across the market ecosystem.

Get StartedCGI ProfileHarris Profile